National Cancer Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Homoharringtonine as an Anticancer Agent

Riepilogo

The Department of Health and Human Services (DHHS) seeks a pharmaceutical company that can effectively pursue the clinical development of Homoharringtonine for the treatment of cancer. The National Cancer Institute has established that this agent may be effective in treating several types of cancers. The selected sponsor will be awarded a CRADA for the development of this agent. The term of the CRADA is anticipated to be three (3) to five (5) years.